Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Vir Biotechnology Inc (Vir Biotechnology) is a is a clinical-stage biopharmaceutical company that focuses on leveraging the immune system to address unmet medical needs. Its activities include the development of antibody-based medicines and protease-releasable masking technologies for infectious diseases and cancer. Vir Biotechnology's pipeline products include tobevibart + elebsiran, for hepatitis delta; tobevibart + elebsiran ± PEG-IFN-α, for hepatitis B; VIR-5818 (HER2) ± pembrolizumab, VIR-5500 (PSMA), and VIR-5525 (EGFR) for solid tumors. Its products are used in therapeutic areas such as chronic hepatitis, oncology, and infectious diseases like COVID-19 and Ebola. The company's technology platform includes dAIs (data AI structure and antibody), and PRO-XTEN. The company operates in the US, and Switzerland. Vir Biotechnology is headquartered in San Francisco, California, the US.
Headquarters
United States of America
Address
Suite 900, 1800 Owens Street, San Francisco, California, 94158
Website
www.vir.bio/
Telephone
1 415 9064324
No of Employees
367
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VIR (NASD)
Revenue (2024)
$68.6M
-7.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
16.1%
(2024 vs 2023)
Market Cap*
$1.6B
Net Profit Margin (2024)
XYZ
9.2%
(2024 vs 2023)
* As of and is in US$
Vir Biotechnology Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | dAIsY |
| tobevibart + elebsiran: Hepatitis Delta | PRO-XTEN |
| tobevibart + elebsiran ± PEG-IFN-α: Hepatitis B | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In September, the company signed an exclusive worldwide license agreement with Sanofi to authorize access to multiple clinical-stage T-cell engagers (TCEs) and the PRO-XTEN masking platform. |
| 2024 | Contracts/Agreements | In February, the company terminated its agreement with GSK to research, develop and leverage the biotech’s monoclonal antibodies for the prevention, treatment, or prophylaxis of the influenza virus. |
| 2024 | Regulatory Approval | In December, the company received the U.S. Food and Drug Administration Breakthrough Therapy designation and European Medicines Agency Priority Medicines (PRIME) designation for bevibart and elebsiran to treat patients with chronic hepatitis delta. |
Competitor Comparison
| Key Parameters | Vir Biotechnology Inc | Gilead Sciences Inc | Alnylam Pharmaceuticals Inc | Moderna Inc | Dynavax Technologies Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Francisco | Foster City | Cambridge | Cambridge | Emeryville |
| State/Province | California | California | Massachusetts | Massachusetts | California |
| No. of Employees | 367 | 17,000 | 2,500 | 4,700 | 405 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Vicki Sato, Ph.D | Chairman | Executive Board | 2016 | 76 |
| Marianne De Backer, Ph.D. | President; Principal Executive Officer; Chief Executive Officer; Director | Executive Board | 2026 | 57 |
| Jason O’Byrne | Chief Financial Officer; Executive Vice President | Senior Management | 2024 | 57 |
| Maninder Hora, Ph.D. | Executive Vice President; Chief Technical Officer; Chief Operating Officer | Senior Management | 2024 | - |
| Mark Eisner, MD | Executive Vice President; Chief Medical Officer | Senior Management | 2024 | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer